Here, we combine unbiased small RNA sequencing with targeted miRNA validation, multiplex cytokine profiling, and parallel characterization of circulating and mucosal CD4+ T-cell subsets in a strictly therapy-naïve IBD cohort. This evidence concerns the gene CD4 and irritable bowel syndrome.